MAJOR LATE TOXICITIES AFTER CONFORMAL RADIOTHERAPY FOR NASOPHARYNGEAL CARCINOMA-PATIENT- AND TREATMENT-RELATED RISK FACTORS

被引:100
|
作者
Lee, Anne W. M. [1 ]
Ng, W. T. [1 ]
Hung, W. M. [1 ]
Choi, C. W. [1 ]
Tung, Raymond [3 ]
Ling, Y. H. [1 ]
Cheng, Peter T. C. [1 ]
Yau, T. K. [1 ]
Chang, Amy T. Y. [1 ]
Leung, Samuel K. C. [2 ]
Lee, Michael C. H. [2 ]
Bentzen, Soren M. [4 ]
机构
[1] Pamela Youde Nethersole Eastern Hosp, Dept Clin Oncol, Chaiwan, Hong Kong, Peoples R China
[2] Pamela Youde Nethersole Eastern Hosp, Dept Med Phys, Chaiwan, Hong Kong, Peoples R China
[3] Hong Kong Canc Fund, Hong Kong, Hong Kong, Peoples R China
[4] Univ Wisconsin, Dept Human Oncol, Sch Med & Publ Hlth, Madison, WI USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2009年 / 73卷 / 04期
关键词
Nasopharyngeal carcinoma; Late toxicity; Concurrent chemotherapy; Radiation boost; SENSORINEURAL HEARING-LOSS; ACCELERATED FRACTIONATION; CONCURRENT CHEMORADIOTHERAPY; THERAPEUTIC GAIN; NORMAL TISSUE; TUMOR-CONTROL; LOCAL-CONTROL; CHEMOTHERAPY; CANCER; RADIATION;
D O I
10.1016/j.ijrobp.2008.05.023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To retrospectively analyze the factors affecting late toxicity for nasopharyngeal carcinoma. Methods and Materials: Between 1998 and 2003, 422 patients were treated with a conformal technique with 2-Gy daily-fractions to a total dose of 70 Gy. Conventional fractionation (5 fractions weekly) was used in 232 patients and accelerated fractionation (6 fractions weekly) in 190 patients. One hundred seventy-one patients were treated with the basic radiotherapy course alone (Group 1), 55 patients had an additional boost of 5 Gy in 2 fractions (Group 2), and 196 patients underwent concurrent cisplatin-based chemotherapy (Group 3). Results: The 5-year overall toxicity rate was significantly greater in Group 3 than in Group 1 (37% vs. 27%, p 0.009). Although the overall rate in Group 2 was not elevated (28% vs. 27%, p = 0.697), a significant increase in temporal lobe necrosis was observed (4.8% vs. 0%,p = 0.015). Multivariate analyses showed that age and concurrent chemotherapy were significant factors. The hazard ratio of overall toxicity attributed to chemotherapy was 1.99 (95% confidence interval, 1.32-2.99,p = 0.001). The mean radiation dose to the cochlea was another significant factor affecting deafness, with a hazard ratio of 1.03 (95 % confidence interval, 1.01-1.05, p = 0.005) per 1-Gy increase. The cochlea that received >50 Gy had a significantly greater deaf rate (Group 1, 18% vs. 7%; and Group 3, 22% vs. 14%). Conclusion: The therapeutic margin for nasopharyngeal carcinoma is extremely narrow, and a significant increase in brain necrosis could result from dose escalation. The significant factors affecting the risk of dearness included age, concurrent chemoradiotherapy, and greater radiation dose to the cochlea. (C) 2009 Elsevier Inc.
引用
收藏
页码:1121 / 1128
页数:8
相关论文
共 28 条
  • [1] Late toxicities after intensity-modulated radiotherapy for nasopharyngeal carcinoma: patient and treatment-related risk factors
    Zeng, L.
    Tian, Y-M
    Sun, X-M
    Chen, C-Y
    Han, F.
    Xiao, W-W
    Deng, X-W
    Lu, T-X
    BRITISH JOURNAL OF CANCER, 2014, 110 (01) : 49 - 54
  • [2] Late toxicities after intensity-modulated radiotherapy for nasopharyngeal carcinoma: patient and treatment-related risk factors
    L Zeng
    Y-M Tian
    X-M Sun
    C-Y Chen
    F Han
    W-W Xiao
    X-W Deng
    T-X Lu
    British Journal of Cancer, 2014, 110 : 49 - 54
  • [3] Patient- and treatment-related risk factors associated with neck muscle spasm in nasopharyngeal carcinoma patients after intensity-modulated radiotherapy
    Zhang, Lu-Lu
    Zhou, Guan-Qun
    Qi, Zhen-Yu
    He, Xiao-Jun
    Li, Jia-Xiang
    Tang, Ling-Long
    Mao, Yan-Ping
    Lin, Ai-Hua
    Ma, Jun
    Sun, Ying
    BMC CANCER, 2017, 17
  • [4] Patient- and treatment-related risk factors associated with neck muscle spasm in nasopharyngeal carcinoma patients after intensity-modulated radiotherapy
    Lu-Lu Zhang
    Guan-Qun Zhou
    Zhen-Yu Qi
    Xiao-Jun He
    Jia-Xiang Li
    Ling-Long Tang
    Yan-Ping Mao
    Ai-Hua Lin
    Jun Ma
    Ying Sun
    BMC Cancer, 17
  • [5] Increased treatment-related mortality with additional cisplatin-based chemotherapy in patients with nasopharyngeal carcinoma treated with standard radiotherapy
    Zhang, An-Mei
    Fan, Ye
    Wang, Xin-Xin
    Xie, Qi-Chao
    Sun, Jian-Guo
    Chen, Zheng-Tang
    Zhu, Bo
    RADIOTHERAPY AND ONCOLOGY, 2012, 104 (03) : 279 - 285
  • [6] Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy
    Lin, Yun-Hsuan
    Huang, Tai-Lin
    Chien, Chih-Yen
    Chen, Hui-Chun
    Hsu, Hsuan-Chih
    Huang, Eng-Yen
    Wang, Chong-Jong
    Huang, Yu-Jie
    Wang, Yu-Ming
    Huang, Chun-Chieh
    Chou, Shang-Yu
    Liao, Kuan-Cho
    Fang, Fu-Min
    RADIATION ONCOLOGY, 2018, 13
  • [7] Risk factors of secondary cancer in nasopharyngeal carcinoma patients after radiotherapy
    Wang, Wen-Jie
    Li, Miao
    Pan, Xin-Bin
    JOURNAL OF CANCER, 2022, 13 (13): : 3452 - 3462
  • [8] Clinical Characteristics and Prognostic Factors of Early and Late Recurrence After Definitive Radiotherapy for Nasopharyngeal Carcinoma
    Li, Feng
    Chen, Fo-Ping
    Chen, Yu-Pei
    Chen, Yue
    He, Xiao-Jun
    Huang, Xiao-Dan
    Zheng, Zi-Qi
    Zheng, Wei-Hong
    Liu, Xu
    Sun, Ying
    Zhou, Guan-Qun
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [9] Risk factors of early thyroid dysfunction after definitive radiotherapy in nasopharyngeal carcinoma patients
    Lian, Chen-Lu
    Zhuo, Ren-Gong
    Zhou, Rui
    Yu, Yi-Feng
    Zhou, Ping
    Lin, Qin
    Wu, San-Gang
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2023, 45 (09): : 2344 - 2354
  • [10] Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer
    Ohe, Y
    Yamamoto, S
    Suzuki, K
    Hojo, F
    Kakinuma, R
    Matsumoto, T
    Ohmatsu, H
    Nishiwaki, Y
    EUROPEAN JOURNAL OF CANCER, 2001, 37 (01) : 54 - 63